PATENTLY ABSURD
AFTER all the laurels and accolades for developing a new-generation vaccine against COVID-19 at the height of the pandemic, the two competing companies that developed the mRNA jabs are facing off in a critical patent dispute. The outcome of the big-ticket litigation will determine how accessible the mRNA technology will be in developing future vaccines and therapies against a host of health hazards, ranging from influenza to cancer.
It took the industry by surprise when after a year of doing business peaceably and earning billions of dollars each, Moderna filed a patent infringement suit against its rival, PfizerBioNTech on August 26. BioNTech and Moderna had both developed their COVID-19 vaccines using the mRNA platform to attack the SARS-CoV-2 virus. While BioNTech, a biotechnology startup in Germany, tied up with multinational Pfizer for quick development of the Comirnaty vaccine, Moderna chose to go it alone to make its Spikevax vaccine.
Now, Moderna claims Pfizer-BioNTech has infringed three patents on its vaccine delivery system, which gets the drug inside a recipient's cells and generates a protein. In lawsuits filed in the US District Court for the District of Massachusetts and the Higher Regional Court of Düsseldorf, where BioNTech is based, Moderna says that Comirnaty infringes patents it had filed between 2010 and 2016 covering the company's "foundational mRNA technology". It accuses its competitor of copying "this groundbreaking technology" which was critical to the development of its own Spikevax.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.